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Background: Mutation-caused loss-of-function of factors involved in DNA damage
response (DDR) is responsible for the development and progression of ~20% of
prostate cancer (PCa). Some mutations can be used in cancer risk assessment and
informed treatment decisions.
Methods: Target capture-based deep sequencing of 11 genes was conducted with total
DNA purified from the proband’s peripheral blood. Sanger sequencing was conducted to
screen potential germline mutations in the proband’s family members. Targeted
sequencing of a panel of 1,021 genes was done with DNA purified from the tumor tissue.
Results: Two previously unreported germline mutations in the DDR pathway, BRCA2
(c.8474_8487delCATACCCTATACAG, p.A2825Vfs*15) and PALB2 (c.472delC,
p.Q158Rfs*19) were identified in a patient with metastatic PCa. A specific therapeutic
regimen including androgen deprivation therapy, locally radical radiotherapy, and
systemic platinum chemotherapy worked well against his cancer. In addition, the
metastatic ovarian cancer in the proband’s half-sister harboring the same BRCA2
germline mutation also responded well to platinum chemotherapy.
Conclusions: The newly identified germline mutations in DDR plays important role in
PCa development. Since specific regimen worked well against this cancer, screening of
DDR mutation could provide better management for patients with these mutation-
mediated PCa.
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INTRODUCTION
Prostate cancer (PCa) is the most prevalent cancer in men and the
second leading cause of cancer-related death worldwide. It has been
estimated that in the United States there will be 191,930 new PCa
diagnoses and 33,330 PCa-related deaths in 2020 (1). Compared
with the general population, first-degree relatives of men with PCa
have approximately twice the risk of developing PCa (2) and genetic
mutations are responsible for ~42% of this disease (3). Genome-
wide association studies have identified more than 100 common
variants that account for approximately 33% of familial PCa risk (4).
Multiple lines of evidence suggest that mutation in genes involved in
DNA damage response (DDR) plays rather important role in cancer
development and progression (5–7).
It has been estimated that the mutation of genes in DDR is
responsible for at least 19% of localized PCa (6) and 23% of
metastatic castration-resistant PCa (7). Proteins encoded by
BRCA2, BRCA1, ATM, CHEK2, PALB2, and mismatch repair
(MMR) genes including MSH2 and MSH6 play important role in
DDR (7). Mutations in some of these genes have already been used
for risk assessment and treatment decision-making (8). For
example, germline mutation of BRCA usually confers a more
aggressive PCa with higher Gleason scores (9), a higher
probability of nodal involvement, distant metastasis, and shorter
overall survival (10). More importantly, patients with advanced PCa
harboring DDR gene mutations generally respond well to poly
(ADP) ribose polymerase (PARP) inhibitors and platinum-based
chemotherapy (11, 12). The U.S. Food and Drug Administration
(FDA) recently approved two poly-ADP ribose polymerase (PARP)
inhibitors, olaparib (11, 13), and rucaparib (14), as treatments for
patients with metastatic castration resistant adenocarcinoma of the
prostate harboring deleterious or suspected deleterious germline or
somatic HRR gene-mutations. Therefore, the stratification of PCa
patients with mutations in DDR pathway may lead to more
informed therapies.
We here report a patient withmetastatic PCa carrying previously
unreported germline mutations in BRCA2 and PALB2, two
important players in DDR. More importantly, this patient
responded well to a specific therapeutic regimen including
androgen deprivation therapy, locally radical radiotherapy, and
systemic platinum chemotherapy. In addition, his half-sister
carrying the same BRCA2 mutation with metastatic ovarian
cancer responded equally well to platinum chemotherapy.
MATERIALS AND METHODS
Patients
All procedures involving human participants were carried out in
accordance with ethical standards of the institutional research
committee at the Army Medical University in Chongqing, China
and with the 1964 Helsinki Declaration and its later amendments
or comparable ethical standards. All patients provided written,
informed consent for review of their medical record and
sequence of their primary and/or metastatic PCa tissue. The
research was conducted with Army Medical University
IRB approval.
Identification of the Mutations
Total DNA was extracted from either the patient’s leukocytes,
primary PCa, or metastatic lung cancer tissues using the
QIAamp DNA Micro Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. Target capture-
based deep sequencing (BGI Health, China) was conducted to
screen potential mutations in a panel of 11 genes (ATM, BRCA1,
BRCA2, MLH1, MLH3, MSH2, MSH3, MSH6, PALB2, PMS1,
and PMS2) using DNA purified from the proband’s peripheral
blood. Sanger sequencing was conducted to screen potential
germline mutations in the proband’s family members. Targeted
sequencing of a panel of 1021 genes (Supplementary Table S1)
was done with DNA purified from the tumor tissue by Geneplus-
Beijing Institute (Beijing, China).
RESULTS
Case Presentation
The proband is a 48-year-old Chinese male who presented to our
department on July 4, 2018 after having hematuria for 2 months.
Digital rectal examination found the right lobe of his prostate is
hardened with irregularities. Laboratory tests showed a relatively
normal level of total serum PSA (prostate-specific antigen, 3.03
ng/ml). Pelvic magnetic resonance imaging (MRI) showed a
lesion (3.1 × 4.3 cm) in the peripheral zone of the right lobe of
his prostate with a low-intensity signal on T2 weighted imaging
(Figures 1A, upper panel). Ultrasound-guided transrectal
prostate biopsies were conducted and pathological examination
showed prostate adenocarcinoma in 4 of the 14 cored biopsies
with an average Gleason score 4 + 4. Computed tomography
(CT) chest scan also revealed two small lesions in his right lung
(Figures 1B, C, upper panel). Whole body positron emission
tomography (PET)-CT scan found hypermetabolic lesions in
both his prostate and right side of lung, but not in the bone or
other organs. Immunohistochemistry of the lesions from the
right lung showed positive staining of PSA and negative staining
of CDX-2 and TTF-1 (data not shown). Therefore, his diagnose
was a primary PCa with lung metastasis (T2cNxM1c).
Identification of Germline and Somatic
Mutations
Given that (i) the relative early-onset and high aggressiveness of
cancer, (ii) his father died of lung cancer at the age of 70, and (iii)
his half-sister suffered from metastatic ovarian cancer with severe
ascites in her early 60s, we decided to screen potential germline
mutations. To do so, DNA extracted from the patient’s leukocytes
was used for sequencing 11 genes involved in the DDR pathway
Abbreviations: DDR, DNA damage response; PCa, Prostate cancer; MMR,
mismatch repair; PARP, poly (ADP) ribose polymerase; PSA, prostate-specific
antigen; MRI, magnetic resonance imaging; CT, Computed tomography; PET,
Positron emission tomography; ADT, androgen deprivation therapy; EBRT,
External Beam Radiation Therapy; HR, homologous recombination; DSBR,
double strand break repair.
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including ATM, BRCA1, BRCA2, MLH1, MLH3, MSH2, MSH3,
MSH6, PALB2, PMS1, and PMS2. Two previously unreported
germline mutations of BRCA2 (c.8474_8487delCATACCCT
ATACAG, p.A2825Vfs*15, Figure 2A) and PALB2 (c.472delC,
p.Q158Rfs*19, Figure 2B) were identified. These deletions result
in the expression of truncated BRCA2 and PALB2. Next, leukocyte
DNA was isolated from the other 10 immediate family members
of the proband and used for Sanger sequencing of the BRCA2 and
PALB2 genes. The characteristics of the family members and their
genetic mutations were summarized in Table 1. Based on the
pedigree (Figure 2C), we postulated that the proband inherited his
mutant BRCA2 allele from his father and the mutant PALB2 from
his mother and therefore the proband carries a heterozygous
mutation of both BRCA2 and PALB2. We then decided to
screen any potential somatic mutations. Total DNA extracted
from both his prostate and lung cancer tissues was used to
sequence a panel of 1021 genes highly involved in PCa. In
addition to the germline mutant BRCA2 and PALB2, 10 and 9
additional somatic mutations were identified in his prostate and
lung lesions, respectively (Supplementary Table S2). Of note, the
six mutations with the highest frequency (>10%) including PAG1
(c.702A>T, p.K234N), KDM5C (c.1869G>C, p.L623F), CDH11
(c.1048G>A, p.A350T), AFF2 (c.124_141delGATCTC
TTTTCTTCAGGC, p.D42_G47del), FOXA1 (c.753_764delCAA
CATGTTCGA, p.M253_N256del), and HCLS1 (c.2_7dupTGT
GGA, p.M1_W2dup) were identical in both the lung and the
prostate lesions. These data strongly suggest that the lesions in his
right lung were metastasized from his PCa.
Treatments and Responses
The treatment regimen for the proband is shown in Figure 3A.
Based on the recommendation from the NCCN guideline for M1
A B C
FIGURE 1 | The radiographs of the proband before and during the treatment. (A–C) The pelvic MRI (A) and chest CT (B, C) scan of the proband before and after
the systematic treatment.
TABLE 1 | The characteristics of the patient and his family members.
Individuals Gender Age (years old) Carrying mutations With Cancers
The proband Male 48 BRCA2 and PALB2 Prostate cancer
His father Male Died at 70 BRCA2 Lung cancer
His mother Female 80 PALB2 Not yet
His son Male 16 No No
His daughter Female 19 BRCA2 Not yet
The proband’s half-sister Female 60 BRCA2 Ovarian cancer
Her son Male 36 Unknown Unknown
The proband’s older brother Male 54 BRCA2 and PALB2 Unknown
His son Male 31 BRCA2 Not yet
The proband’s younger brother Male 45 PALB2 Not yet
His son Male 24 No No
His daughter Female 9 PALB2 Not yet
The proband’s sister Female 51 No No
Her son Male 30 Predicted No Predicted No
Her daughter Female 22 Predicted No Predicted No
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castration-naive PCa (15), primary ADT (androgen deprivation
therapy) with Goserelin (10.8mg sc 1/3months) started on the
date of diagnosis and continued for the rest of the treatment.
Between June 29, 2018, and November 20, 2018, six cycles of
chemotherapy with the combination of nedaplatin (130 mg,
formula: 75 mg/m2 × body surface area) and docetaxel (130
mg, formula: 75 mg/m2 × body surface area) were administrated.
His body surface area was about 1.75 m2 based on the formula
0.0061 × height (167 cm) + 0.0124 × weight (60 kg)-0.0099. In
addition, EBRT (External Beam Radiation Therapy; 66 Gy/30 F,
2.2 Gy/F) was applied to the local primary PCa between June 4th
and June 25th. Only mild adverse events such as slightly reduced
leucocyte count were seen during the whole regimen. Workup to
evaluate the treatment included the levels of serum PSA and
testosterone (Supplementary Table S3), bone imaging, Chest
CT and pelvic MRI without contrast. Figure 3B showed that the
level of serum testosterone decreased to castrated level 4 months
after the beginning of ADT. The levels of serum TPSA became
and remained nearly undetectable 5 months after the start of




FIGURE 2 | Identification of mutations in the proband and his family members. (A, B) Sequencing reads of BRCA2 (A) and PALB2 (B) are shown by the Integrative
Genomic Viewer. (C) The pedigree of mutations.
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after the start of the treatment. Pelvic MRI (March 2, 2019)
revealed that the prostate volume shrank markedly and the
tumor was barely detectable (Figure 1A, bottom panel) 10
months after the start of ADT. Chest CT scans conducted on
September 26, 2018 (Figures 1B, C, middle panel) and March 1,
2019 (Figures 1B, C, bottom panel) and PET-CT examination
on October 3, 2019 (data not shown) found that the lesions in his
right lung disappeared completely. ADT has been continued
without any sign of disease progression up to the preparation of
this report. In addition and according to the recommendation of
the NCCN guideline (16), we have also treated his half-sister’s
metastatic ovarian cancer with platinum-based chemotherapy.
After six cycles of chemotherapy, her general vital signs
including appetite and physical energy improved greatly. More
importantly, the ascites disappeared, and the tumors in her
ovaries and abdominal cavity did not progress as of the
preparation of this report.
DISCUSSION
We report in this study a PCa patient carries previously
unreported germline mutation of BRCA2 and PALB2 and the
same BRCA2 mutation was found in his half-sister who suffered
from metastatic ovarian cancer. In addition, the PCa in the
proband has also metastasized to his right lung. The DNA
sequencing of the proband’s family members showed that the
proband’s brother carries the same BRCA2 and PALB2
mutations. In addition, six individuals carry either the mutant
BRCA2 (three individuals) or PALB2 (three individuals) in his
first- and second-degree relatives (Figure 2C). The proband
underwent ADT and platinum-based chemotherapy as well as
local radiation for his PCa, and his half-sister with metastatic
ovarian cancer was treated with standard platinum-based
chemotherapy. Both patients responded extremely well to the
regimens, although the follow-up duration is relatively short.
Particularly, the proband was found with an undetectable level of
PSA, barely detectable PCa, and totally disappeared lung
metastases after the systemic treatments.
Germline mutation in genes involved in Lynch syndrome
(MSH2, MSH6, and MLH1) and those in homologous
recombination (BRCA1, BRCA2, ATM, PALB2, and CHEK2)
increase not only the incidence but also aggressiveness of
multiple cancer types including prostate, breast, and ovarian
cancer. Cancers with these mutations usually also have poorer
outcomes (17, 18). Consistent with the findings that mutations of
genes in the DDR pathway such as BRCA2, PALB2, and ATM play
important roles in PCa (19), we report a PCa patient with BRCA2
and PALB2 double mutations. Germline BRCA2 mutations were
found in 5.35% of PCa patients from Caucasian (4) and 6.3% from
A
B
FIGURE 3 | Treatment regimens and laboratory test results during and after the treatment. (A) therapeutic schedules for the proband. (B) Serum levels of TPSAand
testosterone in the proband during and after treatment. TPSA, total prostate-specific antigen.
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Chinese population (20). BRCA2 is a protein comprised of 3418
amino acid residues and functions as a scaffold to form a
multiprotein complex with Rad51, BRCA1. This complex acts as
a caretaker of genome integrity by enabling HR (homologous
recombination)-based double-strand DNA break repair and intra-
S phase DNA damage checkpoint control. The germline mutant
BRCA2 (c.8474_8487delCATACCCTATACAG, p.A2825Vfs*15)
identified in this research encodes a truncated protein with 2840
amino acid and lack the 578 residuals at its C-terminus. Since the
function of BRCA2 is severely affected when the 110 residuals at its
C-terminus are lost (21), the truncated BRCA2 identified in the
current report likely encode a loss-of-function BRCA2. Previous
studies have demonstrated that loss of heterozygosity (LOH)
occurred in most of BRCA carriers, including 100% ovarian
cancer with germline BRCA1 mutation (22) and 67% PCa with
germline BRCA2mutation (23). Therefore, we evaluated the LOH
of BRCA2 and PALB2 in our case by using allele frequency
comparisons (22). Based on the HE staining of the biopsy
specimens, we estimated the percentage of tumor cells in the
biopsy specimens and found that ~80% of the lung biopsy tissue is
composed of tumor cells. However, only about 50% of the prostate
biopsy sample is tumor cells. We have also noticed that the variant
allele frequencies (VAF) of the mutation PAG1 (c.702A>T) in the
lung and prostate biopsy samples were 73.8% and 48.2%
(Supplementary Table S2), respectively, proportional to the
abovementioned tumor cell percentage, which indicating that
the mutation was homozygous. Since the VAF of BRCA2 in
lung and prostate biopsy tissues are very close to that of PAG1
in these tissues, we inclined to conclude that BRCA2 mutation in
both lung and PCa cells is homozygous resulted from loss-of-
heterozygosity in both cancers. On the other hand, since the VAF
of PALB2 is about 50% of PAG1’s VAF in both tissues, we
conclude that loss-of-heterozygosity did not happen to PALB2
gene in these cancer cells. However, due to lacking any
experimental evidence, we were unable to unequivocally
conclude that either or both of them are driver genes in PCa
development. Nevertheless, based on their roles in DNA damage
repair especially additional 10 and 9 somatic mutations were
found in prostate and lung lesions, respectively (Supplementary
Table S2), we propose that these mutations play important roles in
PCa initiation/progression.
Multiple lines of evidence indicate that PCa with germline
BRCA2 mutations is more aggressive than those with sporadic
mutations (17, 18). In addition, double mutations of members in
the DDR pathway not only confer an early onset but also a more
aggressive phenotype of the tumors (24, 25). The proband also
carries a germline mutation in PALB2 (c.472delC, p.Q158Rfs*19),
another member of the DDR pathway. It has reported that the
mutant PALB2 (c.1592delT) encodes a loss-of-function PALB2
(26), which is unable to mediate BRCA2 nuclear localization/
accumulation and led to HR/DSBR (double strand break repair)
deficiency (27). Since the truncated peptide expressed in the
proband is even shorter than the previously reported PALB2
expressed from the PALB2 (c.1592delT), it is conceivable that the
DDR pathway in the proband with co-mutation of BRCA2 and
PALB2 would be affected more severely than those with either one
alone. Since the PCa of the proband is encapsulated (T2c) and the
level of TPSA (3.03 ng/ml) is not elevated, the tumor in his
prostate is likely to be still at its early stage. However, given that (i)
his lung cancer is positive of PSA and negative of both CDX-2 and
TTF-1, (ii) the extremely high similarity between the mutations
found in the lung and prostate lesions with the top six mutations
identical, he was diagnosed as a primary PCa with lung
metastases, an extremely rare case. Since the PCa has already
metastasized to the lung but not the lymph node nor the bone
although these organs are the most common metastatic sites of
PCa (28), we speculated that PCa with germline co-mutation of
BRCA2 and PALB2 might be more aggressive. Therefore, his
brother carrying the same double mutations could also have a
higher risk of developing an advanced PCa.
Visceral metastases are commonly associated with advanced
castration-resistant PCa, prolonged treatment, and neuroendocrine
PCa (29, 30). Primary PCa with solitary lung metastasis has rarely
been reported with a low incidence of 0.2% (31) and we report a
PCa patient with solitary distant metastases to the lung who was
found with germline co-mutation of BRCA2 and PALB2. A recent
study (32) has shown that mHSPC (metastatic Hormone-Sensitive
Prostate Cancer) with lung-only metastases might be an unique
molecular and clinical subgroup with significant enrichment for
MMR (25%) andHDR (25%)mutations. Of note, two patients with
solitary lung metastases were found with germline mutations of
BRCA2. Moreover, that study demonstrated that these patients
showed favorable clinical outcomes to first-line ADT treatments.
Although ADT is the gold standard for patients with metastatic
PCa, a universally accepted regimen for these kinds of patients is
lacking. Based on the report that (i) mCRPC in patients with
biallelic mutant BRCA2 responded well to platinum chemotherapy
(33) and (ii) localized PCa with mutant BRCA can be treated with
radiotherapy effectively (34, 35), we carefully crafted a regimen
tailored to the proband (Figure 3A) and the patient responded to
the treatment well (Figure 3B). In addition, his half-sister with
metastatic ovarian cancer and the same germline mutation of
BRCA2 also responded to platinum-based chemotherapies
particularly well. Since cells with HR-deficiencies cannot repair
DNA-damage efficiently, the cancer cells in the patients reported
here would be more prone to chemo- and/or radiotherapy-
mediated cancer cell apoptosis (36–38). We do acknowledge that
an 18-month follow-up for PCa is too short to make any solid
conclusion for the long-term effect of this regimen. The finding
reported here are the first of its kind. We believe that longer follow-
up and further research on a larger cohort of patients with these
mutations will undoubtedly provide a more solid conclusion for the
long-term effect of our therapeutic regimen. In addition, we could
not simply attribute the current therapeutic effect to platinum
chemotherapy, because ADT and docetaxel might also result in
favorable outcomes during such short follow-up (32). Even so, the
therapeutic effect of platinum chemotherapy on this patient should
be highlighted. Just as Mark M. Pomerantz et al. showed that
carboplatin-based chemotherapy could render better prognosis in
patients with BRCA2 germline mutations than those without (39),
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although BRCA2 mutations are associated with more aggressive
PCa. Given that PARP inhibitor olaparib and rucaparib can
improve progression-free survival for mCRPC patients with
mutations in DNA-repair genes (11), olaparib and rucaparib
could be an alternative treatment for patients with BRCA2 and/
or PALB2 mutations. TOPARP-A (11) and TOPARP-B (13) trails
have revealed that olaparib, an orally bioavailable inhibitor of the
catalytic activity of PARP1 and PARP2, has antitumor activity
against metastatic castration-resistant PCa with specific DDR gene
aberrations. More recently, the phase II TRITON2 study has found
that the PARP inhibitor rucaparib has antitumor activity in
mCRPC patients with a deleterious BRCA alteration (14) and
specific non-BRCA DDR gene (e.g., PALB2) alteration (40). In
addition, additional clinical trials are in progress for talazoparib,
velinarib and niraparib (41).
In summary, we identified two previously unreported germline
mutations in the DNA double-strand repair pathway, BRCA2 and
PALB2 in a PCa patient with solitary lung metastasis but without
bone lesion (T2cNxM1c). Since there is no consensus treatment
for these patients, we designed a therapeutic regimen including
androgen deprivation therapy, systemic platinum chemotherapy
and locally radical radiotherapy specifically tailored to his prostate
tumor and the patient responded well. These findings support the
guidelines and consensus statements from international clinical
organizations (42, 43) that recommend DDR mutation screening
for the management of particular PCa patients. More importantly,
these newly identified mutations in DDR are associated with PCa
and can serve as the base for designing personalized treatment.
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